Inmune Bio Inc Stock Price, News & Analysis

On December 6, 2022, INmune Bio presented findings at the 45th San Antonio Breast Cancer Symposium, highlighting the combination of INB03™ and trastuzumab-deruxtecan for treating HER2+ breast cancer. This combination could reverse resistance to HER2-targeted therapies, enhancing treatment efficacy and reducing toxicity. MUC4, a biomarker of resistance, is downregulated by INB03™, which improves anti-tumor immune responses. Key results showed significant tumor growth inhibition when INB03™ was included, with no added toxicity. This may lead to further immunotherapy opportunities for patients resistant to existing treatments.

INmune Bio will participate in the 15th CTAD Conference from November 29 to December 2 in San Francisco. The company is focused on developing therapies targeting Alzheimer's Disease (AD) through an innovative Phase 2 program using novel biomarkers and strategic trial design. Their XPro™ treatment aims to halt the progression of AD by utilizing unique patient criteria, cutting-edge neuroimaging technologies, and an effective cognitive endpoint called EMACC. INmune believes that their approach will surpass traditional anti-amyloid therapies.

INmune Bio has received a "No Objection Letter" from Health Canada to commence its Phase II trial using XPro1595 for mild Alzheimer’s Disease. This approval enables patient enrollment in Canada, joining ongoing efforts in Australia and awaiting clearance from the FDA for U.S. participation. The first patient has finished dosing and is enrolled in an extension study. XPro1595 works by inhibiting soluble tumor necrosis factor, potentially reducing neuroinflammation and improving cognition in patients.

INmune Bio reported its Q3 2022 financial results, showing a net loss of approximately $7.7 million, down from $9.5 million in Q3 2021. R&D expenses decreased to $5.2 million from $6.5 million year-over-year. The FDA is reviewing a clinical hold on XPro1595 trials for Alzheimer’s Disease, while patient enrollment for the Phase 2 trial is ongoing in Australia. Positive data was shared regarding the INKmune platform's efficacy against solid tumors. The company holds approximately $57.4 million in cash as of September 30, 2022, with 17.9 million shares outstanding.

INmune Bio (NASDAQ: INMB) announced it will host a conference call on November 2, 2022, at 4:30 PM ET to discuss its third-quarter results for the period ended September 30, 2022. The call will provide important updates on the company’s clinical-stage immunology treatments, which focus on harnessing the innate immune system to combat diseases. Notable products, INB03™ and XPro™, are under clinical trials targeting cancer and neurodegenerative diseases. Investors can join via a [live audio webcast](https://www.globenewswire.com/Tracker?data=jni87MnRMi1SJ_fIn5KPNuQg5GFixjb5sEr92-ts9gQK1hhT6EDFSgA5BW2IybxjB_Tm96tsj81J07gj9mqa9mt5ZJ8XnV4lpwJxNdPaMwjg_Mwg2krbA9nimtaw6G69hAyfAcvTnGgZvtVR28TJ4vntC84o5VjjX1he2ny1ornTKsLLXqYj5RBDX9RwiILUPZ5r9UnWt1Ab2gBWySFf1nxecypEkzIeqBqTe7zjRUU=).

INmune Bio, Inc. (NASDAQ: INMB) presented promising data on INKmune, a treatment aimed at solid tumors, at the Innate Killer Summit Europe on October 19, 2022. Solid tumors account for 90% of adult cancers, yet most therapies target liquid tumors. INKmune enhances the ability of Natural Killer (NK) cells to attack NK-resistant cancer types, including prostate, ovarian, renal, and nasopharyngeal cancers. Notably, INKmune-primed NK cells showed a 66% lysis rate on DU145 prostate cells compared to less than 4% for unprimed cells. This data supports the transition of INKmune trials towards solid tumors, potentially benefiting over 4 million patients in the US.

INmune Bio (NASDAQ: INMB) announced that RJ Tesi, M.D., CEO, will present at two upcoming conferences: the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 4:00 pm ET in New York, and the Baird Global Healthcare Conference on September 14, 2022, at 3:45 pm ET. Both events will include one-on-one meetings with management. The company focuses on creating treatments that leverage the innate immune system against diseases, with products in clinical trials targeting multiple conditions.

INmune Bio reported its Q2 2022 financial results and business update, highlighting the dosing of the first patient in a Phase II trial for Alzheimer’s using XPro™. The FDA review concerning a clinical hold on XPro1595 is ongoing. The company has sufficient doses for ongoing trials and has presented promising data on XPro™ and INB03 at various conferences. Financially, INmune posted a net loss of $6.8 million, slightly up from $6.7 million last year, with $61.2 million in cash as of June 30, 2022. Shares outstanding are approximately 17.9 million.

INmune Bio, Inc. will host a conference call on August 3, 2022 at 4:30 PM ET to discuss its Q2 2022 results and provide a corporate update. Participants can join by dialing 1-877-407-0784 (or 1-201-689-8560 internationally) and entering conference ID 13728540. The live webcast will also be available. INmune Bio focuses on developing therapies targeting the innate immune system for diseases such as cancer and Alzheimer's.